Business Context and Reporting Period
This Form 8-K filing by ImmudYne, Inc. (not Lifemd, Inc.) reports on a Special Meeting of Shareholders held on June 4, 2018. The company is incorporated in Delaware and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and shareholder voting results.
Material Changes and Voting Results
Shareholders approved two critical proposals at the Special Meeting:
- Proposal 1 (Name Change): Approved to change the company name to Conversion Labs, Inc.
- Votes For: 32,020,414
- Votes Against/Withheld: 722,393
- Abstentions: 442,524
- Proposal 2 (Reverse Stock Split Authorization): Approved to authorize a reverse stock split of up to 1-for-6 for a 12-month period.
- Condition: The split will only be effected in connection with an application to list on a national securities exchange (NYSE, NYSE American, or NASDAQ).
- Votes For: 28,574,983
- Votes Against/Withheld: 3,858,196
- Abstentions: 752,152
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or specific risk factors beyond the conditional nature of the reverse stock split. The primary contingency is that the reverse stock split is dependent on a successful listing application on a national exchange.
Investor Verification Checklist
- Verify the official name change to Conversion Labs, Inc. with the relevant state and exchange authorities.
- Monitor for a subsequent filing or press release confirming the execution of the reverse stock split and the specific ratio chosen.
- Confirm the company's application status for listing on NYSE, NYSE American, or NASDAQ.
- Review the company's most recent 10-K or 10-Q for financial data, as this 8-K contains no financial metrics.